The report showed that the vaccination rate has quintupled over the last decade.
More senior Americans than ever before are reporting that they’ve been vaccinated against shingles, according to newly published data from the CDC’s National Center for Health Statistics. Although the shingles vaccination rate is now almost 35% nationally, there are racial, economic, and educational disparities among those receiving the vaccine.1
The National Health Interview Survey focused on the 10 years between 2008 and 2018. During that time, the national shingles vaccination rate among adults aged 60 and older rose from 6.7% in 2008 to 34.5% in 2016, and then remained constant through 2018. Rates for adults aged 70 and over were even higher, ranging from 7.8% in 2008 to 37.8% in 2016, which also held constant through 2018. The higher rates surpassed the CDC’s Healthy People 2020 target of 30% for shingles vaccination.1
Other key findings of the survey include:1
“While there has been a shingles vaccine [Zostavax] available since 2006, a new vaccine [Shingrix] was introduced in late 2017, and uptake in the market may have occurred differentially in 2018,” noted the authors of the report.1
They also found that the discontinuation of Zostavax in the United States—announced by Merck in May with an effective date of July 1, 2020—may further alter shingles vaccination patterns in the future. Additionally, the 2017 recommendation by the CDC’s Advisory Committee on Immunization Practices (ACIP), which expanded shingles vaccination to adults aged 50 and over, may also impact future vaccination rates.1
Supply shortages of Shingrix developed shortly after its introduction in the US market, but FiercePharma recently reported that the COVID-19 pandemic led to a drop-off in vaccinations, allowing GlaxoSmithKline (GSK) to catch up on production of its shingles vaccine.2
A company spokesman reported that GSK has produced “without interruption” during the pandemic. As a result, Shingrix is no longer listed on the CDC’s shortages list, and GSK assured its customers that it has supplies “available to meet demand across all distribution channels.”
References:
FDA Issues CRL for Heplisav-B in Adults With ESRD on Hemodialyis
May 14th 2024Dynavax plans to meet with the FDA to discuss how the company can provide additional data to support the approval of its 4-dose Heplisav-B regimen and expand protection for adults with end-stage renal disease (ESRD) on hemodialysis.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.